Assistant Clinical Professor, Anesthesiology
School of Medicine
B.A., Kalamazoo College, 2003, Chemistry
Ph.D., Vanderbilt University, 2009, Pharmacology
M.D., Michigan State College of Human Medicine, 2012
Phone: (949) 824-7246
University of California, Irvine
101 The City Drive South, B53-226G, Orange CA 92868
Irvine, CA 92697
Pain Medicine, Opioid Use Reduction, Regional Anesthesia
2021 Southern California Super Doctors Rising Star Honoree
2021 Orange County Physician of Excellence Nominee
2015 Midwest Anesthesia Research Conference, Third Place
2007 Society for Redox Biology and Medicine Young Investigator Award
2003 Dan May Research Fellowship at Vanderbilt University
2002 Howard Hughes Medical Institute Research Award
Dr. Aaron Przybysz is a board-certified Anesthesiologist and Pain Management physician. Dr. Przybysz earned his medical degree from Michigan State University’s College of Human Medicine in East Lansing, MI, and a PhD in Pharmacoloy from Vanderbilt University in Nashville, TN, where he studied signaling pathways associated with the oxidative stress response. He completed a residency in Anesthesiology and a Fellowship in Pain Medicine from the University of Michigan in Ann Arbor, MI. Dr. Przybysz currently practices medicine in Orange County, CA and was recently nominated for the 2021 Physicians of Excellence honor by the Orange County Medical Association.
Dr. Przybysz has published numerous peer-reviewed research articles and has been invited to give lectures on various medical and scientific topics on the local, state, and national level. His current areas of research include the genetic response to oxidative stress and aging, the use of perioperative and intraoperative analgesic techniques to reduce post-operative pain, examining the phenomenon of opioid-induced hyperalgesia, as well as studying the role cannabinoids may play in treating acute and chronic pain.
1. Prieto, A. R., Przybysz, A. J., and Fischell, T. A. (2002). Long Balloon Angioplasty with Focal Stenting for the Treatment of Diffuse Coronary Artery Disease. Catheter. Cardiovasc. Interv. 57, 437-443.
2. Choe, K. P., Przybysz, A. J., and Strange, K. (2009). The WD40 Repeat Protein WDR-23 Functions with the CUL4/DDB1 Ubiquitin Ligase to Regulate Nuclear Abundance and Activity of SKN-1 in Caenorhabditis elegans. Mol. Cell Biol. 29, 2704-2715.
3. Przybysz, A. J., Choe, K. P., Roberts, L. J., and Strange, K. (2009). IncreasedAge Reduces DAF-16 and SKN-1 Signaling and the Hormetic Response of Caenorhabditis elegans to the Xenobiotic Juglone. Mech. Ageing Dev. 130, 357-369.
4. Wu, C., Deonarine, A., Przybysz, A. J., Strange, K., and Choe, K. (2016). The Skp1 Homologs SKR-1/2 are Required for the Caenorhabditis elegans SKN-1 Antioxidant/Detoxification Response Independently of p38 MAPK. PLoS Genet. 2016 Oct 24; 12(10).
ASA, CSA, ASRA, AMA